Table 1 Baseline characteristics and drug usage in patients over a 3-month observation period

From: Significance of estimated salt excretion as a possible predictor of the efficacy of concomitant angiotensin receptor blocker (ARB) and low-dose thiazide in patients with ARB resistance

n

 

93

Age (years)

 

67.7±12.6

Male (n)

 

55 (59.1%)

BMI (kg m−2)

 

24.6±3.6

Obesity (n(%))

 

32 (34.4%)

Diabetes (n(%))

 

20 (21.5%)

Chronic kidney disease (n(%))

 

21 (22.6%)

Dyslipidemia (n(%))

 

41 (44.1%)

Cerebrovascular diseases (n(%))

 

15 (16.1%)

Acute coronary syndrome (n(%))

 

4 (4.3%)

Pre-prescribed ARB

n (%)

Average doses (mg per day)

Olmesartan

25 (26.9)

20.0

Losartan

22 (23.7)

50.0

Valsartan

18 (19.4)

92.5

Telmisartan

14 (15.1)

38.7

Candesartan

11 (11.8)

7.6

Irbesartan

3 (3.2)

100.0

Total

93 (100)

—

  1. Abbreviations: ARB, angiotensin receptor blocker; BMI, body mass index.
Back to article page